Category Archives: Public Policy

Latest From Public Policy

IP Position Critical to Biotech Investment

A great article from Genetic Engineering and Biotechnology News written by Lisa Haile reviewing the Myriad case and its implications for future medical advances. Interesting Quotes: “While it is unfortunate, I have seen quite a few technologies over the years that would be of potential great benefit to patients, but the intellectual property was simply not there to support protecting the product from fast followers in the market place,” explains Robert More, a general partner Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

2011 BIO International Convention Super Sessions

2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

BIO submits comments on Australian Senate Patent Amendment

The Australian Senate has proposed the Patent Amendment (Human Genes and Biological Materials) Bill 2010 that aims to ban ‘gene patents’.  From the BIO Submission to Australian Senate Legal Committee on Patent Amendment: This amendment would exclude from patent protection “any” biological material, whether a human gene or otherwise, that is substantially identical to a naturally-occuring biological material.  Specifically, the amendment states that the following materials would be catergorically declared unpatentable:             “biological materials including their components Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , ,

BIO Comments to USTR on 2011 Special 301 Review

BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

WSJ: “Patent Office to Get a Boost”

An article from the Wall Street Journal regarding the Adminstration’s budget proposal for the Patent Office.  Highlights: WASHINGTON—The Obama administration’s budget blueprint for fiscal 2012 seeks to boost the speed and quality of services of the U.S. Patent and Trademark Office, including through the use of temporary surcharges on patent fees. The Obama administration said the fee surcharge, along with regulatory and legislative reforms, would provide the Patent Office with $2.7 billion in resources in Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,